<< BackAtriCure Launches the AtriClip® FLEX•V™ Device in the United States
New device builds on the “V” clip technology, offering increased flexibility in left atrial appendage management
MASON, Ohio--(BUSINESS WIRE)--Feb. 22, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management (LAAM), today announced that it has launched the AtriClip FLEX•V™ Left Atrial Appendage (LAA) Exclusion System in the United States. The new AtriClip FLEX•V is the first device of the AtriClip family to offer a clip deployment trigger release. The device also offers an open-ended AtriClip design combined with a tip-first closure mechanism to enable easier navigation and placement in cardiac surgeries. This “V” clip technology builds off the AtriClip PRO•V, which was launched in September of 2017 for minimally-invasive surgery (MIS) applications. The AtriClip FLEX•V received 510(k) clearance in January of 2018.
In 2010, AtriCure became the first company to receive clearance for a left atrial appendage management device. Since then, over 125,000 AtriClip devices have been sold worldwide. With new innovations and technology, AtriCure continues to increase left atrial appendage management and enhance open-concomitant cardiac surgery to help patients worldwide.
“The AtriClip FLEX•V is an exciting new product that we are pleased to be releasing to our U.S. customers,” said Mike Carrel, President, and CEO of AtriCure. “This product will enable easier AtriClip deployment in open-chest surgeries, as it combines the lower-profile “V” Clip technology with a redesigned handle enabling a one-handed operation of the device. To date, we have successfully placed over 200 AtriClip PRO•V devices since we launched in September of 2017, and this innovation builds off that momentum. We are excited to see how many more patients we can impact with the addition of the AtriClip FLEX•V to the AtriClip franchise.”
The AtriClip FLEX•V has a rotatable and malleable shaft allowing cardiac surgeons and hospital staff to adjust the AtriClip to adapt to specific patient anatomies. In addition, the new clip opening handle offers a reduced fatigue design to reposition the AtriClip multiple times before deployment to ensure the device is extended beyond the LAA and at the base.
To date, AtriClip products are the most widely sold LAA management device worldwide with more than 125,000 implanted. For more information about the AtriClip franchise including the new AtriClip FLEX·V, visit https://www.atricure.com/atrial-occlusion.
About AtriCure, Inc.
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide, with more than 125,000 implanted to date. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180222005210/en/
Source: AtriCure, Inc.
Valerie Storch-Willhaus, 612-605-3311
Director, Corporate Marketing, and Communications
Andy Wade, 513-755-4564
Senior Vice President and Chief Financial Officer